# Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children.

*biotech · news · 2026-04-22 · The Manila Times*

## Key points

- The FDA expanded Tzield's approval to children as young as one year with stage 2 T1D.
- Tzield is now the first disease-modifying therapy for stage 2 T1D in children aged one and above.
- Approval was based on one-year data from the PETITE-T1D phase 4 study in young children.
- Previously, Tzield was only approved for patients eight years and older with stage 2 T1D.

**Companies:** Sanofi
**Countries:** US, France, UK, China, Canada, Israel, Saudi Arabia, UAE, Kuwait, Brazil

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/22/tmt-newswire/globenewswire/press-release-sanofis-tzield-approved-in-the-us-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children/2325671)

---

Canonical: https://newsio.io/n/2a8e2ce8-a8a1-4e7d-9c47-af6c4ee9b766/sanofis-tzield-approved-in-the-us-to-delay-the-onset-of-stage-3-type-1-diabetes
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works